Your Position:Home>Products>Monoclonals/Polyclonals>Anti-Human CD152/CTLA4 & PD-1 Bispecific Reference Antibody

Anti-Human CD152/CTLA4 & PD-1 Bispecific Reference Antibody

  • Cat. No.:RB9THB651086
  • Price:Negotiable
  • Clicks:189

Product Detail

Product Parameters

FormLiquid
Host SpeciesHumanized
ClonalityMonoclonal
Isotype[V-kappa’-VH-h-CH2-CH3_V-kappa-VH’]2
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration1mg/ml
Endotoxin LevelPlease contact the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetCD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Expression SystemMammalian Cells
Accession NumberP16410 & Q15116
BackgroundLorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
• Cancer immunotherapy using checkpoint blockade., PMID:29567705
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• Immune-related adverse events of checkpoint inhibitors., PMID:32382051
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113
• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885
• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160
• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858
• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360
• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Alternative NamesTetravalentBispecific, MGD019, MGD-019, MGD0192416595-46-3
NoteFor research use only. Not suitable for clinical or therapeutic use.
For Research Use Only. Not for Diagnostic Procedures.

Related Products:
Total 33055 records,Divided into 1653 pages,The 1 pages | First Prev Next Last
Live Chat
  • Tel:
  • WeChat ID: 15898894496
  • Add Message
  • 9:00 AM – 6:00 PM